Prescribing information and adverse event reporting information can be accessed using the PI & AE button at the side.
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1
Restorative sleep and Daytime functioning with QUVIVIQ™ (daridorexant) 50 mg1-4
QUVIVIQ™ is NICE recommended and SMC accepted for restricted use for the treatment of chronic insomnia in adults5,6*
For adults with chronic insomnia whose daytime functioning is considerably affected, consider offering QUVIVIQTM, only if cognitive behavioural therapy for insomnia (CBTi) has been tried but not worked, or is unavailable or unsuitable.5,6
NICE recommends QUVIVIQ™ as a cost-effective option for patients with chronic insomnia.5
- Treatment duration should be as short as possible5,6
- Patients should be assessed within 3 months of starting QUVIVIQ™ 5,6
- Treatment should be stopped in those whose long-term insomnia has not responded adequately5
- If treatment is continued, assess whether it is still working at regular intervals5,6
*For adults with chronic insomnia with symptoms lasting for 3 nights or more per week5 for at least 3 months and whose daytime functioning is considerably affected, only if CBTi has been tried but not worked or is unavailable or unsuitable. The length of treatment should be for as short as possible.5,6
How is chronic insomnia defined?
- Difficulty getting to sleep or maintaining sleep, early wakening, or non-restorative sleep resulting in impaired daytime functioning or wellbeing7
- AND symptoms occur on at least 3 nights per week for 3 months or more7
Many people struggle with the symptoms and health consequences of untreated insomnia.8
Understanding chronic insomnia: a self‑led learning programme comprises six interactive modules covering a range of topics including:
Patient identification and management
Sleep mechanisms and QUVIVIQ™ action
The impact of insomnia
NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines Consortium
This medicine is subject to additional monitoring.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Idorsia at ds.safety.uk@idorsia.com.
This information is intended for UK healthcare professionals.
References
- QUVIVIQ™ (daridorexant) Summary of Product Characteristics
- Mignot E, Mayleben D et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double‑blind, placebo‑controlled, phase 3 trials. Lancet Neurol 2022;21:125‑139
- Robbins R, Quan S F et al. A nationally representative survey assessing restorative sleep in US adults. Front Sleep 2022;1:935228
- Kunz D, Dauvilliers Y et al. Long‑term safety and tolerability of daridorexant in patients with insomnia disorder. CNS Drugs 2023;37:93-106
- National Institute for Health and Care Excellence (NICE). Technology appraisal guidance 922. Daridorexant for treating long-term insomnia, 18 October 2023. Available at: nice.org.uk. Accessed July 2025
- Scottish Medicines Consortium (SMC). SMC2611. Daridorexant film-coated tablets (Quviviq®), 8 April 2024. Available at: scottishmedicines.org.uk. Accessed June 2025
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. Arlington, VA, American Psychiatric Publishing, 2022
- Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007;3:S7-10
© NICE 2023. Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/TA922. All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.
UK-DA-00913 | Last updated: July 2025
QUV-Pro.idorsia QUVIVIQ Homepage_June 2025
